Exploring a better way to patient care

Autoimmune diseases can involve virtually any cell or organ system, and have a global prevalence around 345,000,000 today. Compare that to the global prevalence of cancer at 12,740,000, and you start to see the vast impact these diseases have. 

With such an enormous need, we’re focused on the discovery of new biomarkers and systems that enables more accurate and early diagnosis. Through novel biomarkers like HMGCR, PS/PT and CCP3 we provide clinicians with the tools to make more accurate diagnoses, earlier in the disease process — so that people suffering from autoimmune diseases can begin treatment as soon possible to positively impact the course of the disease.